[(1h-1,3-Benzodiazol-2-yl)methyl]({3-ethoxy-4-[(thiophen-2-yl)methoxy]phenyl}methyl)amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: [(1h-1,3-Benzodiazol-2-yl)methyl]({3-ethoxy-4-[(thiophen-2-yl)methoxy]phenyl}methyl)amine
• 英文别名: N-(1H-benzimidazol-2-ylmethyl)-1-[3-ethoxy-4-(thiophen-2-ylmethoxy)phenyl]methanamine
• 化学式: C₂₂H₂₃N₃O₂S
• 分子量: 393.5
• InChiKey: WPKVLNVHJJPTEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  87.4
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] METHODS FOR DISRUPTING MITOCHONDRIAL UNFOLDED PROTEIN RESPONSE<br/>[FR] PROCÉDÉS POUR PERTURBER UNE RÉPONSE DE PROTÉINE DÉPLIÉE MITOCHONDRIALE
  申请人：[en]HEALTH RESEARCH, INC.

  公开号：WO2022103897A1

  公开（公告）日：2022-05-19

  The present disclosure provides methods for treating an individual in need of treatment of conditions in which HSP60/ClpP expression and/or binding is abnormal with a composition having a compound having the following structure: Formula (I) The methods may be used to disrupt mitochondrial unfolded protein response. In various examples, a compound of the composition binds to heat shock protein 60 (HSP60) and inhibits the interaction of HSP60 to ClpP, thus interrupting the mitochondrial unfolded protein response. For example, the composition may be used as a therapeutic approach for treating advanced prostate cancers that are no longer sensitive to AR targeted therapies.